Presentations

Showing 1–12 of 28 results

Presentations [PEGS 2024] Fast-tracking Checkpoint Antibody Development with MOA-Reflective Assays for Cancer & Autoimmune Therapeutics

Checkpoint blockade antibodies are established cancer therapeutics. However, in recent years, agonistic antibodies have emerged as therapeutics not only for…

Read More
Presentations Ion Channel Drug Discovery Webinar – Recent Advances in Novel Non-opioid Pain research

In this webinar, Eurofins DiscoverX and Latigo Therapeutics come together to present recent advances in ion channel drug discovery focusing…

Read More
Presentations Advancing Therapeutics Targeting Cytokines with Functional Cell-based Assays

Jennifer Lin-Jones, Ph.D., Associate Director of Assay Development R&D Department, Eurofins DiscoverX

Read More
Presentations [SBS 2009] Cell-based Receptor Tyrosine Kinase Screening Reloaded – Development of a new cellular assay system for a target protein so far resistant against HTS formats

Read More
Presentations [PEGS 2023] Accelerating Immuno-Oncology Drug Discovery with MOA-Reflective, Functional Cell-Based Assays

Venkatesh Chari, Ph.D. Scientific Market Development Manager Eurofins DiscoverX Products LLC

Read More
Presentations [EU PEGS 2022] Implementing MOA-Reflective Cytotoxicity Assays Using Ready-to-Use KILR®Target & Effector Cells from Screening to Lot Release

Andrew Green Sr. Business Development Manager

Read More
Presentations [Biophysical Society 2023] Characterization of Two Eurofins DiscoverX’s PrecisION® Nicotinic Cell Lines Using Automated Electrophysiology

Drug Discovery for Ion Channels XXIII Satellite Meeting

Read More
Presentations [IO Summit 2022] Implementing MOA-Reflective ADCC & ADCP Cytotoxicity Assays Using Ready-to-Use KILR® Target & Effector Cells from Screening to Lot Release

Jane E. Lamerdin, Ph.D. Vice President, Research & Development Eurofins DiscoverX

Read More
Presentations Using DiscoverX’s ADP QuestTM for Academic Screening of Novel Kinases

Read More
Presentations [WCBBA 2022] Accelerating Potency Bioassay Implementation from Development to QC Lot-Release & Ensuring Long-term Assay Reproducibility

Alpana Prasad, Ph.D. Director, Innovations and Strategic Partnership

Read More
Presentations [WCB 2020] Accelerate Your COVID-19 Drug Discovery with Qualified Cell-Based Assays for Proinflammatory Cytokines

Gaurav Agrawal, Ph.D. Scientific Development Manager, Eurofins DiscoverX

Read More
Presentations [PEGS 2022] Implementing MOA-Reflective ADCC Assays using Ready-to-Use KILR Target and Effector Cells from Screening to Lot Release

Gaurav Agrawal, Ph.D.Scientific Development Manager

Read More
Contact